Actinium Pharmaceuticals, Inc. (ATNM) Fair Value 2026

ATNM · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

6.0 /10

32 fundamental signals · 1 models active

Value Trap Risk

LOW (35/100)

Quick Summary — As of 2026-08-28, Actinium Pharmaceuticals, Inc. (ATNM) trades at $1.01. QOC: 6.0/10. Value Trap Risk: 35/100 (LOW). 1/13 models active.

Key Facts

Ticker
ATNM
Price
$1.01
Quality Score
6.0/10
Value Trap Risk
35/100
Models Active
1/13
Last Updated
Strength: Regime Cross-Sectional suggests +13.3% upside with 16% confidence
Risk: Limited model coverage (1/13) may reduce confidence

What Fair Value Does Each Model Give ATNM?

1 Intrinsic Value Models vs. Current Price ($1.01)

Core Models (Unlocked)
Model Fair Value Upside
Relative · Low Conviction
 $1.14 +13.3%

All Models Active

All 1 models are displayed above.

What Is Actinium Pharmaceuticals, Inc. (ATNM) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Actinium Pharmaceuticals, Inc.'s intrinsic value is estimated at a median fair value of $1.14. At a current market price of $1.01, 1 of 1 active valuation models identify upside potential, projecting a median implied return of +13.3%.

What Do the Models Say About ATNM?

1 of 13 models are currently active for ATNM. All 1 active models suggest the stock trades below fair value. See which stocks rank higher →

How Does ATNM Rank in Biotechnology?

Among 625 Biotechnology stocks, ATNM ranks #152 by Quality of Company score. CirclFi's QOC score of 6.0/10 evaluates 32 fundamental signals. A score of 6.0 reflects mixed fundamentals.

See all Most Undervalued Biotechnology Stocks →

The Biotechnology sector introduces analytical considerations specific to life sciences company businesses. For Actinium Pharmaceuticals, Inc., metrics like market exclusivity window provide important context that general-purpose valuation models may underweight.

Is ATNM a Value Trap?

CirclFi's Value Trap algorithm assigns ATNM a score of 35/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

1 of 13 models are active for Actinium Pharmaceuticals, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Deep Alpha Valuation Engine, Actinium Pharmaceuticals, Inc. scores 6.0 out of 10 on our 32-signal quality assessment, a solid rating that maintains reasonable quality metrics with some areas for improvement. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every ATNM valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across ATNM's 1 active models, average confidence is 16%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Actinium Pharmaceuticals, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

CYTKCytokinetics, IncorporatedQOC 6.0TNXPTonix Pharmaceuticals Holding Corp.QOC 5.9NUVBNuvation Bio Inc.QOC 6.0ABEOAbeona Therapeutics Inc.QOC 5.9RANIRani Therapeutics Holdings, Inc.QOC 6.0RYTMRhythm Pharmaceuticals, Inc.QOC 5.9IMMXImmix Biopharma, Inc.QOC 5.0ALLRAllarity Therapeutics, Inc.QOC 4.4PYPDPolyPid Ltd.QOC 2.0EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: CYTK · TNXP · NUVB · ABEO · RANI · RYTM · IMMX · ALLR · PYPD · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to ATNM?

7 companies across all industries closest to ATNM’s Quality of Company score of 6.0/10.

PRTSCarParts.com, Inc.QOC 6.0VUZIVuzix CorporationQOC 6.0BGINBgin Blockchain LimitedQOC 6.0SPNDSpindletop Oil & Gas Co.QOC 6.0ASSTStrive, Inc.QOC 6.0NXRTNexPoint Residential Trust, Inc.QOC 6.0NVDANVIDIA CorporationQOC 10.0

Read investment analysis: PRTS · VUZI · BGIN · SPND · ASST · NXRT · NVDA

Where Does ATNM Sit in CirclFi's Biotechnology Rankings?

ATNM is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About Actinium Pharmaceuticals, Inc.’s Valuation?

What is Actinium Pharmaceuticals, Inc.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for Actinium Pharmaceuticals, Inc. (ATNM). The Quality of Company score is 6.0/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is ATNM overvalued or undervalued right now?

At $1.01, 1 of 1 active models suggest ATNM may be undervalued, while 0 indicate potential overvaluation. The assessment depends on which methodology best fits Actinium Pharmaceuticals, Inc.'s business model in Biotechnology.

What does a Quality of Company score of 6.0 mean for ATNM?

Actinium Pharmaceuticals, Inc.'s QOC of 6.0/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on ATNM?

CirclFi analyzes ATNM with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 1 of 13 are active for this stock. Read the full methodology →

Is ATNM a value trap in 2026?

Actinium Pharmaceuticals, Inc.'s Value Trap score is 35/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns Actinium Pharmaceuticals, Inc. (ATNM) a Quality of Company score of 6.0/10 across 32 fundamental signals as of 2026-08-28.” Source: circlfi.com/stock/ATNM/ · Methodology
Primary sources for this ATNM valuation
  • Financial statements: Actinium Pharmaceuticals, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001388320) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for ATNM as of ; valuations recomputed .